Search results
Johnson & Johnson plans $850M Proteologix acquisition
NJBIZ· 11 hours agoA May 16 press release announced the all-cash deal. The New Brunswick-based pharma giant said the move will add depth to its dermatology portfolio by boosting its position to address
Coexistence of psoriatic arthritis, atopic dermatitis may offer treatment insights
Medical Xpress· 7 days agoPsoriatic arthritis (PsA) and atopic dermatitis (AD) can coexist, and the presence of both...
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment
Morningstar· 5 days agoProteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic
J&J to Lead in Atopic Dermatitis Treatment with Recent Acquisition
New Jersey Business Magazine· 5 days agoJohnson & Johnson has entered into a definitive agreement to acquire Proteologix, Inc. for $850...
Johnson & Johnson to acquire Proteologix for $850 million
Reuters via Yahoo Finance· 5 days agoProteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic...
Chart Review Highlights Unique AD Features in Older Patients
Medscape· 1 day agoMore research is "needed to elucidate the unique features of elderly AD in pathophysiology and...
What to do about rashes on skin
Rolling Out· 4 days agoRashes on the body can be both uncomfortable and concerning, affecting people of all ages and backgrounds. These skin irritations may range from mild
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Zacks via Yahoo Finance· 4 days agoThis week, Bayer BAYRY released its first-quarter results. J&J JNJ announced that it will acquire a...
Earnings call: Arcutis Biotherapeutics reports strong Q1 2024 growth
Investing.com· 6 days agoArcutis Biotherapeutics (NASDAQ: ARQT ) has announced robust financial results for the first quarter...
Arcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
GuruFocus.com via Yahoo Finance· 6 days agoArcutis Biotherapeutics Inc (NASDAQ:ARQT) is poised for potential market expansion with the upcoming FDA PDUFA target date for its sNDA for atopic dermatitis</ ...